Trial Profile
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART (DIVA): A Single Arm Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Disulfiram (Primary) ; Vorinostat (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DIVA
- 29 Sep 2021 Results published in the AIDS
- 09 Apr 2019 Status changed from suspended to discontinued.
- 07 Mar 2019 Results presented at the 26th Conference on Retroviruses and Opportunistic Infections